Clinical trial
A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of KAN-101 in Patients With Celiac Disease (ACeD)
NCT04248855 is registered in ClinicalTrials.gov with Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of KAN-101 in Patients With Celiac Disease (ACeD)
- Lead sponsor
- Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 21, 2020
- Completion date
- October 8, 2021
- Enrollment
- 41 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.